vs

Side-by-side financial comparison of FTC Solar, Inc. (FTCI) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.

FTC Solar, Inc. is the larger business by last-quarter revenue ($32.9M vs $28.8M, roughly 1.1× X4 Pharmaceuticals, Inc). X4 Pharmaceuticals, Inc runs the higher net margin — 1.0% vs -110.7%, a 111.7% gap on every dollar of revenue.

FTC Solar, Inc. is a leading global provider of advanced solar tracker systems, associated components, and supporting software for solar projects. It serves utility-scale, commercial, and industrial solar segments across key global markets, helping customers boost energy generation efficiency and lower overall project costs.

X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.

FTCI vs XFOR — Head-to-Head

Bigger by revenue
FTCI
FTCI
1.1× larger
FTCI
$32.9M
$28.8M
XFOR
Higher net margin
XFOR
XFOR
111.7% more per $
XFOR
1.0%
-110.7%
FTCI

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
FTCI
FTCI
XFOR
XFOR
Revenue
$32.9M
$28.8M
Net Profit
$-36.4M
$282.0K
Gross Margin
14.9%
83.6%
Operating Margin
-17.2%
-32.8%
Net Margin
-110.7%
1.0%
Revenue YoY
148.9%
Net Profit YoY
-197.4%
100.5%
EPS (diluted)
$-2.31
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FTCI
FTCI
XFOR
XFOR
Q4 25
$32.9M
Q3 25
$26.0M
Q2 25
$20.0M
Q1 25
$20.8M
$28.8M
Q4 24
$13.2M
Q3 24
$10.1M
Q2 24
$11.4M
Q1 24
$12.6M
$0
Net Profit
FTCI
FTCI
XFOR
XFOR
Q4 25
$-36.4M
Q3 25
$-23.9M
Q2 25
$-15.4M
Q1 25
$-3.8M
$282.0K
Q4 24
$-12.2M
Q3 24
$-15.4M
Q2 24
$-12.2M
Q1 24
$-8.8M
$-51.8M
Gross Margin
FTCI
FTCI
XFOR
XFOR
Q4 25
14.9%
Q3 25
6.1%
Q2 25
-19.6%
Q1 25
-16.6%
83.6%
Q4 24
-29.1%
Q3 24
-42.5%
Q2 24
-20.5%
Q1 24
-16.7%
Operating Margin
FTCI
FTCI
XFOR
XFOR
Q4 25
-17.2%
Q3 25
-29.6%
Q2 25
-57.5%
Q1 25
-50.8%
-32.8%
Q4 24
-101.7%
Q3 24
-147.8%
Q2 24
-104.3%
Q1 24
-99.3%
Net Margin
FTCI
FTCI
XFOR
XFOR
Q4 25
-110.7%
Q3 25
-92.0%
Q2 25
-77.2%
Q1 25
-18.4%
1.0%
Q4 24
-92.7%
Q3 24
-151.5%
Q2 24
-107.1%
Q1 24
-69.7%
EPS (diluted)
FTCI
FTCI
XFOR
XFOR
Q4 25
$-2.31
Q3 25
$-1.61
Q2 25
$-1.18
Q1 25
$-0.58
$0.04
Q4 24
$-0.95
Q3 24
$-1.21
Q2 24
$-0.97
Q1 24
$-0.70
$-7.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FTCI
FTCI
XFOR
XFOR
Cash + ST InvestmentsLiquidity on hand
$21.1M
$40.3M
Total DebtLower is stronger
$9.9M
$75.0M
Stockholders' EquityBook value
$-43.0M
$22.9M
Total Assets
$111.8M
$130.0M
Debt / EquityLower = less leverage
3.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FTCI
FTCI
XFOR
XFOR
Q4 25
$21.1M
Q3 25
$24.4M
Q2 25
$3.5M
Q1 25
$5.9M
$40.3M
Q4 24
$11.2M
Q3 24
$8.3M
Q2 24
$10.8M
Q1 24
$14.0M
$60.5M
Total Debt
FTCI
FTCI
XFOR
XFOR
Q4 25
$9.9M
Q3 25
$16.6M
Q2 25
$10.9M
Q1 25
$10.2M
$75.0M
Q4 24
$9.5M
Q3 24
Q2 24
Q1 24
$55.0M
Stockholders' Equity
FTCI
FTCI
XFOR
XFOR
Q4 25
$-43.0M
Q3 25
$-13.7M
Q2 25
$9.0M
Q1 25
$15.5M
$22.9M
Q4 24
$19.0M
Q3 24
$30.4M
Q2 24
$44.2M
Q1 24
$55.2M
$1.0M
Total Assets
FTCI
FTCI
XFOR
XFOR
Q4 25
$111.8M
Q3 25
$111.5M
Q2 25
$83.0M
Q1 25
$84.1M
$130.0M
Q4 24
$89.9M
Q3 24
$91.7M
Q2 24
$100.3M
Q1 24
$115.0M
$112.2M
Debt / Equity
FTCI
FTCI
XFOR
XFOR
Q4 25
Q3 25
Q2 25
1.20×
Q1 25
0.65×
3.27×
Q4 24
0.50×
Q3 24
Q2 24
Q1 24
53.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FTCI
FTCI
XFOR
XFOR
Operating Cash FlowLast quarter
$-8.0M
$-12.4M
Free Cash FlowOCF − Capex
$-8.4M
FCF MarginFCF / Revenue
-25.7%
Capex IntensityCapex / Revenue
1.3%
0.0%
Cash ConversionOCF / Net Profit
-43.86×
TTM Free Cash FlowTrailing 4 quarters
$-34.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FTCI
FTCI
XFOR
XFOR
Q4 25
$-8.0M
Q3 25
$-14.6M
Q2 25
$-2.3M
Q1 25
$-8.5M
$-12.4M
Q4 24
$-16.7M
Q3 24
$-2.4M
Q2 24
$-3.8M
Q1 24
$-11.9M
$-33.6M
Free Cash Flow
FTCI
FTCI
XFOR
XFOR
Q4 25
$-8.4M
Q3 25
$-15.1M
Q2 25
$-2.5M
Q1 25
$-8.6M
Q4 24
$-17.0M
Q3 24
$-2.6M
Q2 24
$-4.5M
Q1 24
$-12.3M
$-33.7M
FCF Margin
FTCI
FTCI
XFOR
XFOR
Q4 25
-25.7%
Q3 25
-57.9%
Q2 25
-12.4%
Q1 25
-41.2%
Q4 24
-128.6%
Q3 24
-25.6%
Q2 24
-39.2%
Q1 24
-97.6%
Capex Intensity
FTCI
FTCI
XFOR
XFOR
Q4 25
1.3%
Q3 25
1.7%
Q2 25
0.9%
Q1 25
0.4%
0.0%
Q4 24
2.2%
Q3 24
2.2%
Q2 24
6.1%
Q1 24
3.4%
Cash Conversion
FTCI
FTCI
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
-43.86×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FTCI
FTCI

Products$26.2M80%
Services$6.7M20%

XFOR
XFOR

Segment breakdown not available.

Related Comparisons